Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

Risk stratification is crucial to treatment decision‐making in neuroblastoma. This study aimed to explore factors present at diagnosis affecting outcome in patients aged ≥18 months with metastatic neuroblastoma and to develop a simple risk score for prognostication.

[1]  A. Naranjo,et al.  Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Günter Schreier,et al.  Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[3]  M. Drobics,et al.  123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  K. Matthay,et al.  Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. , 2016, European journal of cancer.

[5]  Gian Paolo Tonini,et al.  An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma , 2016, Journal of Translational Medicine.

[6]  H. Koo,et al.  Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[7]  M. Bermúdez,et al.  TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients , 2016, Journal of Cancer Research and Clinical Oncology.

[8]  D. Zwijnenburg,et al.  Abstract PR06: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors , 2016 .

[9]  Simon C Watkins,et al.  Telomerase activation by genomic rearrangements in high-risk neuroblastoma , 2015, Nature.

[10]  J. Vandesompele,et al.  Individual patient risk stratification of high‐risk neuroblastomas using a two‐gene score suited for clinical use , 2015, International journal of cancer.

[11]  Ravi Radhakrishnan,et al.  ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. , 2014, Cancer cell.

[12]  B. Hero,et al.  MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Hiroyuki Shimada,et al.  Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ system , 2014, Molecular oncology.

[14]  Derek Stephens,et al.  Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Gregory,et al.  Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  John M Maris,et al.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[17]  A. Naranjo,et al.  Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group , 2013, The Journal of Nuclear Medicine.

[18]  J. Khan,et al.  Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project , 2012, British Journal of Cancer.

[19]  D. Machin,et al.  Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Matthay,et al.  Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force , 2010, British Journal of Cancer.

[21]  Maja Pohar Perme,et al.  Pseudo-observations in survival analysis , 2010, Statistical methods in medical research.

[22]  J Khan,et al.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee , 2009, British Journal of Cancer.

[23]  K. Matthay,et al.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force , 2009, British Journal of Cancer.

[24]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Yang Zhang,et al.  Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project , 2008, Pediatric blood & cancer.

[26]  D. Machin,et al.  High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. , 2008, The Lancet. Oncology.

[27]  John P Klein,et al.  Analyzing survival curves at a fixed point in time , 2007, Statistics in medicine.

[28]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.

[29]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[30]  R. D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions , 2004, Statistics in medicine.

[31]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[32]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[33]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[34]  F. Berthold,et al.  Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. , 1992, The American journal of pediatric hematology/oncology.

[35]  J. Shuster,et al.  Serum Lactate Dehydrogenase in Childhood Neuroblastoma A Pediatric Oncology Group Recursive Partitioning Study , 1992, American journal of clinical oncology.

[36]  O. Borgan.  The Statistical Analysis of Failure Time Data (2nd Ed.). John D. Kalbfleisch and Ross L. Prentice , 2003 .